Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease

Abstract

Dry eye disease (DED) is a multifactorial disease of ocular surface and tear film, and is a common disorder treated by eye care providers. It is well established that ocular surface inflammation has an important role in the pathophysiology of DED and that anti-inflammatory cyclosporine A (CsA) improves the treatment outcomes of most patients with DED. The purpose of this review is to provide guidance for practitioners in the use of topical CsA for the management of DED to improve patient satisfaction and the quality of life.

Keywords:

• keratoconjunctivitis sicca
• dry eye disease
• cyclosporine A

Acknowledgments

This study was supported in part by US Public Health Service grants RO1EY10056 (SEW) and P30-EY025585 from the National Eye Institute, National Institutes of Health, Bethesda, MD and Research to Prevent Blindness, New York, NY.

Disclosure

SEW was a consultant for Allergan in developing and implementing the phase III clinical trials for Restasis. The authors report no other conflicts of interest in this work.